Compound Semaglutide Discontinued? Current Status & Access

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compound semaglutide is not being discontinued. The compounded GLP-1 market remains active and stable through licensed 503A pharmacies, which operate under strict FDA oversight. Recent supply discussions have centered on branded semaglutide (Wegovy, Ozempic) production timelines—not compounded formulations.

This distinction matters because patients considering GLP-1 therapy need accurate information about their options. PlexusDx helps clarify the regulatory foundation, cost structures, and how individual genetic predispositions in peptide pathways may inform which formulation and delivery method best aligns with clinical goals and personal needs.

Compounded vs. Branded Semaglutide: Understanding the Regulatory Difference

Compounded semaglutide and branded semaglutide (Wegovy, Ozempic) are distinct products with different regulatory pathways. Branded versions are manufactured by pharmaceutical companies and FDA-approved; compounded versions are prepared by licensed 503A pharmacies under USP <797> standards. Both pathways are legal and operational.

The 503A regulatory framework ensures that compounded medications meet strict potency, purity, and sterility standards. When supply concerns arise for branded drugs, they do not automatically affect compounded availability. Licensed 503A compounding pharmacies maintain independent supply chains and can continue operations during branded shortages or discontinuations.

Current Market Status: Why Confusion Persists About Discontinuation

Recent media coverage of semaglutide supply challenges has focused primarily on branded Wegovy and Ozempic production delays, not on compounded formulations. This has created confusion among patients about whether the GLP-1 class itself is being discontinued. In reality, compounded semaglutide remains available through licensed pharmacies nationwide.

The compounded GLP-1 market has actually expanded as demand for weight management and diabetes treatment has grown. PlexusDx and similar platforms partner exclusively with licensed 503A compounding pharmacies to ensure consistency, safety, and regulatory compliance. Availability remains stable, and pricing remains predictable through flat monthly commitment tiers.

Product Type	Status	Supply Chain	Regulatory Oversight
Branded Semaglutide (Wegovy, Ozempic)	Subject to supply fluctuations	Manufacturer-dependent	FDA-approved drug
Compounded Semaglutide	Stable and available	Licensed 503A pharmacies	USP <797> standards + state pharmacy boards
Compounded Tirzepatide	Available and growing	Licensed 503A pharmacies	USP <797> standards + state pharmacy boards
Compounded Dual-Peptide Formulations	Available through select providers	Licensed 503A pharmacies	USP <797> standards + state pharmacy boards

Why 503A Compounding Pharmacy Standards Ensure Stability

Licensed 503A compounding pharmacies operate under federal and state oversight that ensures medication quality regardless of market disruptions. Each compounded dose must meet USP <797> sterility and potency standards. These pharmacies are inspected regularly and maintain their own pharmaceutical-grade supply chains independent of major manufacturer production.

Choosing a platform like PlexusDx that partners exclusively with licensed 503A compounders provides transparency and safety. Patients can verify their pharmacy's license and understand that their medication is prepared under controlled conditions—not subject to the same supply-chain vulnerabilities as branded pharmaceuticals from single manufacturers.

Making an Informed Choice: Genetic Predispositions and Formulation Planning

Individual genetic predispositions in GLP-1 receptor pathways and metabolic genes can provide context for which semaglutide formulation or delivery method may be most suitable. Variants in GLP1R and GIPR genes, for example, may relate to how individuals metabolize and respond to GLP-1 medications. This information should be interpreted with a qualified provider.

The Precision Peptide Genetic Test reveals predispositions in peptide pathways that can support a more informed conversation with your healthcare provider about whether compounded semaglutide injection, oral semaglutide, tirzepatide, or a dual-peptide approach aligns best with your individual profile. No genetic test predicts exact medication response, but understanding your metabolic context helps personalize your GLP-1 plan.

How PlexusDx Supports a More Personalized Approach

PlexusDx partners exclusively with licensed 503A compounding pharmacies to provide stable, affordable access to compounded semaglutide and tirzepatide. The distinction between compounded and branded medications is crucial: compounded formulations are not subject to the same supply constraints as branded Wegovy or Ozempic, and they may help provide context for cost-conscious patients evaluating long-term GLP-1 therapy.

The Precision Peptide Genetic Test examines predispositions in key peptide metabolism pathways—including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—that may relate to how your body processes GLP-1 compounds. This test does not predict exact medication response or guarantee outcomes, but reveals predispositions that can support a more personalized conversation with your provider about which formulation and dose escalation strategy may align with your genetic context.

Understanding your genetic predispositions alongside current market facts helps you make a confident, informed decision about compounded GLP-1 therapy. This approach shifts focus from whether medications are being discontinued to what formulation, delivery method, and support framework best matches your individual needs and clinical goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.